Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: Outcomes by intent to treat analyses

被引:27
作者
Weaver, CH [1 ]
West, WH [1 ]
Schwartzberg, LS [1 ]
Alberico, T [1 ]
Leff, R [1 ]
Greco, FA [1 ]
Hainsworth, J [1 ]
Birch, R [1 ]
McAneny, B [1 ]
Magee, M [1 ]
Raefsky, E [1 ]
Kalman, L [1 ]
Buckner, CD [1 ]
机构
[1] RESPONSE ONCOL INC,DIV CLIN RES,MEMPHIS,TN
关键词
high-dose chemotherapy for breast cancer;
D O I
10.1038/sj.bmt.1700728
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We investigated the outcomes of patients with breast cancer undergoing induction chemotherapy, mobilization of peripheral blood stem cells (PBSC) and high-dose chemotherapy (HDC) with PBSC infusion. One hundred and fourteen patients with untreated stage IV breast cancer, with a median age of 46 years (range 24-62), mere entered on a phase II trial consisting of: (1) doxorubicin, 5-flurouracil, methotrexate (AFM) x4 courses at 2 week intervals; (2) cyclophosphamide (4 g/m(2)), etoposide (600 mg/m(2)), cisplatin (105 mg/m(2)) (CEP), filgrastim (6 mu g/kg/day) and PBSC collection; (3) cyclophosphamide (6 g/m(2)), thiotepa (500 mg/m(2)), carboplatin (800 mg/m(2)) (CTCb) followed by PBSC infusion. All patients received AFM 107 (94%) received CEP, 93 (82%) received CTCb and PBSC as per protocol and 99 (87%) ultimately received HDC and PBSC. There was one infectious death after AFM and all other deaths were associated with progressive disease. Fifty-two patients (36%) are alive, 21 (18%) without progression, at a median 31 months (range 22-47). The probabilities of survival and progression-free survival at 3.5 rears were 0.40 and 0.17, respectively. All 62 patients with visceral disease and/or a prior history of doxorubicin adjuvant therapy have relapsed or progressed. We conclude that the sequential administration of BFM, CEP and CTCb followed by PBSC resulted in long-term PFS only in patients who mere NED, had bone-only disease or had lymph node or soft tissue disease with or without bone disease. Other strategies, aimed at improving responses to initial therapy, improving HDC regimens and/or developing immunomodulatory therapies, will be necessary to improve PFS for patients who fail doxorubicin adjuvant or who have visceral disease.
引用
收藏
页码:661 / 670
页数:10
相关论文
共 44 条
[1]   THE EFFECT OF PRIOR ADJUVANT CHEMOTHERAPY ON SURVIVAL IN METASTATIC BREAST-CANCER [J].
AHMANN, FR ;
JONES, SE ;
MOON, TE .
JOURNAL OF SURGICAL ONCOLOGY, 1988, 37 (02) :116-122
[2]  
*AM SOC CLIN ONC A, 1990, J CLIN ONCOL, V8, P563
[3]   A PHASE-II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN WITH AUTOLOGOUS MARROW SUPPORT IN WOMEN WITH MEASURABLE ADVANCED BREAST-CANCER RESPONDING TO STANDARD-DOSE THERAPY [J].
ANTMAN, K ;
AYASH, L ;
ELIAS, A ;
WHEELER, C ;
HUNT, M ;
EDER, JP ;
TEICHER, BA ;
CRITCHLOW, J ;
BIBBO, J ;
SCHNIPPER, LE ;
FREI, E .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :102-110
[4]   PROGNOSTIC FACTORS FOR PROLONGED PROGRESSION-FREE SURVIVAL WITH HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT FOR ADVANCED BREAST-CANCER [J].
AYASH, LJ ;
WHEELER, C ;
FAIRCLOUGH, D ;
SCHWARTZ, G ;
REICH, E ;
WARREN, D ;
SCHNIPPER, L ;
ANTMAN, K ;
FREI, E ;
ELIAS, A .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2043-2049
[5]   Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: No improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin [J].
Ayash, LJ ;
Elias, A ;
Schwartz, G ;
Wheeler, C ;
Ibrahim, J ;
Teicher, BA ;
Reich, E ;
Warren, D ;
Lynch, C ;
Richardson, P ;
Schnipper, L ;
Frei, E ;
Antman, K .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (11) :2984-2992
[6]   DOUBLE DOSE-INTENSIVE CHEMOTHERAPY WITH AUTOLOGOUS MARROW AND PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT FOR METASTATIC BREAST-CANCER - A FEASIBILITY STUDY [J].
AYASH, LJ ;
ELIAS, A ;
WHEELER, C ;
REICH, E ;
SCHWARTZ, G ;
MAZANEF, R ;
TEPLER, I ;
WARREN, D ;
LYNCH, C ;
GONIN, R ;
SCHNIPPER, L ;
FREI, E ;
ANTMAN, K .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) :37-44
[7]  
BENYUNES MC, 1993, BONE MARROW TRANSPL, V12, P159
[8]   RETRACTED: HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS PRIMARY-TREATMENT FOR METASTATIC BREAST-CANCER - A RANDOMIZED TRIAL (Retracted article. See vol. 19, pg. 2973, 2001) [J].
BEZWODA, WR ;
SEYMOUR, L ;
DANSEY, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2483-2489
[9]  
Bitran JD, 1996, BONE MARROW TRANSPL, V17, P157
[10]   TANDEM AUTOTRANSPLANTATION FOR THE TREATMENT OF METASTATIC BREAST-CANCER [J].
BROUN, ER ;
SRIDHARA, R ;
SLEDGE, GW ;
LOESCH, D ;
KNEEBONE, PH ;
HANNA, M ;
HROMAS, R ;
CORNETTA, K ;
EINHORN, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2050-2055